756 related articles for article (PubMed ID: 30045064)
21. Soluble adenylyl cyclase antibody profile as a diagnostic adjunct in the assessment of pigmented lesions.
Magro CM; Crowson AN; Desman G; Zippin JH
Arch Dermatol; 2012 Mar; 148(3):335-44. PubMed ID: 22105816
[TBL] [Abstract][Full Text] [Related]
22. Black lesions of the skin.
BECKER SW
Calif Med; 1958 Mar; 88(3):228-33. PubMed ID: 13511215
[TBL] [Abstract][Full Text] [Related]
23. Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions.
Santandrea G; Valli R; Zanetti E; Ragazzi M; Pampena R; Longo C; Lai M; Piana S; Cesinaro AM
Am J Surg Pathol; 2022 May; 46(5):579-590. PubMed ID: 35275883
[TBL] [Abstract][Full Text] [Related]
24. Performance of PRAME immunohistochemistry compared with that of c-Kit, c-Myc, or cyclin D1 for the diagnosis of acral melanocytic tumors.
Jung JM; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
Pathol Int; 2023 Jan; 73(1):27-36. PubMed ID: 36468840
[TBL] [Abstract][Full Text] [Related]
25. PRAME Immunohistochemical Expression and TERT Promoter Mutational Analysis as Ancillary Diagnostic Tools for Differentiating Proliferative Nodules From Melanoma Arising in Congenital Nevi.
Boutko A; Hagstrom M; Lampley N; Roth A; Olivares S; Dhillon S; Fumero-Velázquez M; Benton S; Zhao J; Zhang B; Dittmann D; Asadbeigi S; Busam KJ; Gerami P
Am J Dermatopathol; 2023 Jul; 45(7):437-447. PubMed ID: 37338065
[TBL] [Abstract][Full Text] [Related]
26. Ex vivo quality-switched ruby laser irradiation of cutaneous melanocytic lesions: persistence of S-100-, HMB-45- and Masson-positive cells.
Kopera D; Hohenleutner U; Stolz W; Landthaler M
Dermatology; 1997; 194(4):344-50. PubMed ID: 9252755
[TBL] [Abstract][Full Text] [Related]
27. Expression of soluble adenylyl cyclase in lentigo maligna: use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and assessment of margins.
Magro CM; Yang SE; Zippin JH; Zembowicz A
Arch Pathol Lab Med; 2012 Dec; 136(12):1558-64. PubMed ID: 23194049
[TBL] [Abstract][Full Text] [Related]
28. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
Lohman ME; Steen AJ; Grekin RC; North JP
J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
[TBL] [Abstract][Full Text] [Related]
29. PRAME expression in melanocytic lesions of the nail.
Parra O; Linos K; Li Z; Yan S
J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
[TBL] [Abstract][Full Text] [Related]
30. PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.
Lezcano C; Jungbluth AA; Busam KJ
Surg Pathol Clin; 2021 Jun; 14(2):165-175. PubMed ID: 34023098
[TBL] [Abstract][Full Text] [Related]
31. PRAME immunohistochemistry of spitzoid neoplasms.
Koh SS; Lau SK; Scapa JV; Cassarino DS
J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
[TBL] [Abstract][Full Text] [Related]
32. Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas.
Gassenmaier M; Hahn M; Metzler G; Bauer J; Yazdi AS; Keim U; Garbe C; Wagner NB; Forchhammer S
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359765
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.
Rawson RV; Shteinman ER; Ansar S; Vergara IA; Thompson JF; Long GV; Scolyer RA; Wilmott JS
Pathology; 2022 Dec; 54(7):863-873. PubMed ID: 35987723
[TBL] [Abstract][Full Text] [Related]
34. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
35. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
36. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions.
Rothrock AT; Torres-Cabala CA; Milton DR; Cho WC; Nagarajan P; Vanderbeck K; Curry JL; Ivan D; Prieto VG; Aung PP
J Cutan Pathol; 2022 Oct; 49(10):859-867. PubMed ID: 35794643
[TBL] [Abstract][Full Text] [Related]
38. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
39. Spontaneous regression of multiple melanocytic nevi after melanoma: report of 3 cases.
Martín JM; Pinazo I; Monteagudo C; Markovic J; Allende A; Jordá E
Am J Dermatopathol; 2014 Nov; 36(11):e183-8. PubMed ID: 25343215
[TBL] [Abstract][Full Text] [Related]
40. PRAME expression in cutaneous melanoma does not correlate with disease-specific survival.
Parra O; Ma W; Li Z; Coffing BN; Linos K; LeBlanc RE; Momtahen S; Sriharan A; Cloutier JM; Wells WA; Yan S
J Cutan Pathol; 2023 Oct; 50(10):903-912. PubMed ID: 37430414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
